Charles River Laboratories Inte
CRL
Positions held
Your positionsCRL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Charles River Laboratories operates in the growing diagnostics and research sector, which is essential for advancing healthcare solutions and has a strong demand due to increasing investments in biotechnology and pharmac
- Revenue increased by 1% compared to the prior quarter, reaching $1.0 billion.
- Gross margin improved to 36.2%, up from 29.6% in the previous quarter.
- The company has faced challenges with a negative revenue growth rate of -2.7%, indicating potential difficulties in maintaining sales momentum.
- Net income was negative at -1.482 million in Q2 2026, reflecting ongoing profitability issues.
- The operating margin has decreased to 11.94% in Q2 2026, down from 12.04% in Q1 2026.
Fundamentals
| Market cap | $14.35B | Enterprise value | $17.12B | Trailing P/E | — | Forward P/E | 23.33 |
| PEG | 0.12 | Price / book | 5.01 | Beta | 1.40 | Dividend yield | 0.00% |
| Revenue growth | -2.7% | Earnings growth | — | Gross margin | 34.6% | Operating margin | 15.1% |
| Profit margin | -6.0% | ROE | -7.5% | ROA | 4.1% | Debt / equity | 1.05 |
| Current ratio | 1.35 | Free cash flow | $468.86M | Analyst recommendation | buy | Mean target | $310.53 |
| 52w high | $333.30 | 52w low | $146.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $996M | $994M | $1.0B | $1.0B |
| Op margin | 11.9% | 12.0% | 9.3% | 13.3% | 9.7% |
| Net income | -$1.5M | -$14.8M | -$277M | $54.4M | $52.3M |
| Gross margin | 36.2% | 29.6% | 31.1% | 33.7% | 34.6% |
| Gross profit | $363M | $295M | $310M | $339M | $357M |
| Operating income | $120M | $120M | $92.5M | $134M | $100M |
- Revenue +1% vs prior quarter ($1.0B vs $996M).
- Gross margin 36.2% (was 29.6% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.1B | $4.0B |
| Op margin | 10.0% | 10.9% | 14.9% | 16.4% |
| Net income | -$144M | $10.3M | $475M | $486M |
| Gross margin | 33.0% | 32.9% | 36.4% | 36.8% |
| Gross profit | $1.3B | $1.3B | $1.5B | $1.5B |
| Operating income | $401M | $442M | $617M | $651M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
2026-10-07 · PGNY or CRL: Which Is the Better Value Stock Right Now?
2026-10-07 · Charles River Gains 75.8% in a Year: What's Driving the Rally?
2026-10-06 · Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
2026-10-06 · Charles River and Autolomous Partner to Transform Laboratory Execution Systems
2026-10-02 · Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
2026-09-30 · UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175
2026-09-30 · Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
2026-09-29 · Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
Price (daily)
Full chart · RSI · MACD · patterns